Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RAMIRIS: Ramucirumab Plus FOLFIRI vs Ramucirumab Plus Paclitaxel in Advanced Gastric Cancer
NCT03081143Phase 3Completed
- Sponsor
- Institut für Klinische Krebsforschung
- Start
- May 2017
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised trial of FOLFIRI in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (2 arms), sponsored by Institut für Klinische Krebsforschung. Primary endpoints: Overall Survival Rate at 6 months, Overall Survival and 1 more. Started May 2017; status: completed.
02
Drugs
FOLFIRI
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03081143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03081143.